Acacia Pharma has its own commercial infrastructure in the US through which it markets and sells its products directly.
Outside the US, the Company intends to commercialize Barhemsys® and APD403 via licensing and/or distribution agreements with selected pharmaceutical partners. Acacia Pharma currently holds global rights to both products.
The Company will continue to assess further hospital opportunities to utilize its US sales and marketing infrastructure, including in-licensing or acquiring complementary product candidates, as it did with Byfavo®, which it in-licensed from Cosmo Pharmaceuticals in January 2020.
To discuss opportunities, please contact email@example.com.